61 related articles for article (PubMed ID: 6093720)
1. Structure activity relationships of resorcinol substituted ring systems.
Ilhan M; Long JP; Flynn J; Bhatnagar R; Cannon JG
Arch Int Pharmacodyn Ther; 1984 Sep; 271(1):22-32. PubMed ID: 6093720
[TBL] [Abstract][Full Text] [Related]
2. Conformationally restricted congeners of dopamine derived from octahydrobenzo[g]quinoline and octahydrobenzo[f]quinoline.
Cannon JG; Hamer RL; Ilhan M; Bhatnagar RK; Long JP
J Med Chem; 1984 Feb; 27(2):190-5. PubMed ID: 6694167
[TBL] [Abstract][Full Text] [Related]
3. Congeners of the beta conformer of dopamine derived from cis- and trans-octahydrobenzo[f]quinoline and trans-octahydrobenzo[g]quinoline.
Cannon JG; Lee T; Goldman HD; Long JP; Flynn JR; Verimer T; Costall B; Naylor RJ
J Med Chem; 1980 Jan; 23(1):1-5. PubMed ID: 7188974
[TBL] [Abstract][Full Text] [Related]
4. p-Dimethoxy-substituted trans-octahydrobenzo[f]- and -[g]quinolines: synthesis and assessment of dopaminergic agonist effects.
Cannon JG; Amoo VE; Long JP; Bhatnagar RK; Flynn JR
J Med Chem; 1986 Dec; 29(12):2529-34. PubMed ID: 3783613
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic structure-activity relationships of 2-aminoindans and cardiovascular action and dopaminergic activity of 4-hydroxy, 5-methyl, 2-di-n-propylaminoindan (RD-211).
Ma SX; Long JP; Flynn JR; Leonard PA; Cannon JG
J Pharmacol Exp Ther; 1991 Feb; 256(2):751-6. PubMed ID: 1671601
[TBL] [Abstract][Full Text] [Related]
6. TL-350, an ergoline derivative with dopamine receptor agonist properties.
Ilhan M; Long JP; Bhatnagar R; Flynn J; Cannon JG; Lee T
J Pharmacol Exp Ther; 1984 Oct; 231(1):56-60. PubMed ID: 6548524
[TBL] [Abstract][Full Text] [Related]
7. Cis- and trans-4-n-Propyl-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolines.
Cannon JG; Koble-Suarez C; Long JP; Ilhan M; Bhatnagar RK
J Pharm Sci; 1985 Jun; 74(6):672-5. PubMed ID: 4040568
[TBL] [Abstract][Full Text] [Related]
8. Dopamine receptor stimulating and alpha adrenoceptor blocking actions of trans (CS-265) and cis (CS-263) isomers of nonhydroxylated N-propyl octahydrobenzo[F]quinoline.
Ilhan M; Long JP; Cannon JG
J Pharmacol Exp Ther; 1984 Nov; 231(2):361-6. PubMed ID: 6149308
[TBL] [Abstract][Full Text] [Related]
9. II. Pharmacological studies with derivatives of 2-aminotetralin, benzhydro[f]quinoline, benzhydro[g]quinoline, apomorphine and clonidine suggest a pharmacological dissimilarity between peripheral presynaptic dopamine receptors and alpha-2 adrenoceptors.
Maixner W; Flynn JR; Arnerić SP; Cannon JG; Long JP
J Pharmacol Exp Ther; 1983 Feb; 224(2):352-8. PubMed ID: 6296357
[TBL] [Abstract][Full Text] [Related]
10. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor stimulating activity of 5-hydroxy-6-methyl-2-aminotetralin derivatives.
Verimer T; Long JP; Bhatnagar RK; Koble DL; Cannon JG; Flynn JR; Goodale DB; Arnerić SP
Arch Int Pharmacodyn Ther; 1981 Apr; 250(2):221-41. PubMed ID: 6791601
[TBL] [Abstract][Full Text] [Related]
12. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
Seiler MP; Markstein R
Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
[TBL] [Abstract][Full Text] [Related]
13. Resorcinol congeners of dopamine derived from benzocycloheptene and indan.
Cannon JG; Pease JP; Hamer RL; Ilhan M; Bhatnagar RK; Long JP
J Med Chem; 1984 Feb; 27(2):186-9. PubMed ID: 6319700
[TBL] [Abstract][Full Text] [Related]
14. Differential activation by some 2-aminotetralin derivatives of the receptor mechanisms in the nucleus accumbens of rats which mediate hyperactivity and stereotyped biting.
Costall B; Naylor RJ; Cannon JG; Lee T
Eur J Pharmacol; 1977 Feb; 41(3):307-19. PubMed ID: 556988
[TBL] [Abstract][Full Text] [Related]
15. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
[TBL] [Abstract][Full Text] [Related]
16. N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies.
Tagmatarchis N; Thermos K; Katerinopoulos HE
J Med Chem; 1998 Oct; 41(21):4165-70. PubMed ID: 9767652
[TBL] [Abstract][Full Text] [Related]
17. Activity of N-(2-phenylethyl)-N-n-propyl-2-(3-hydroxyphenyl) ethylamine derivatives as dopamine receptor ligands.
Claudi F; Cardellini M; Di Stefano A; Giorgioni G; Cantalamessa F; Renò F; Balduini W
Drug Des Discov; 1994 Feb; 11(2):115-25. PubMed ID: 7915549
[TBL] [Abstract][Full Text] [Related]
18. 5,7-Dihydroxy-2-aminotetralin derivatives: synthesis and assessment of dopaminergic and adrenergic actions.
Cannon JG; Brubaker AN; Long JP; Flynn JR; Verimer T; Harnirattisai P; Costall B; Naylor RJ; Nohria V
J Med Chem; 1981 Feb; 24(2):149-53. PubMed ID: 7205882
[TBL] [Abstract][Full Text] [Related]
19. Correlation of alpha- and beta-rotameric forms of 2-substituted octahydrobenzo[f]quinoline dopamine congeners with high and low affinity states of the anterior pituitary dopamine receptor and prolactin inhibition.
Findell PR; Torkelson SM; Craig JC; Weiner RI
Mol Pharmacol; 1988 Jan; 33(1):78-83. PubMed ID: 3336350
[TBL] [Abstract][Full Text] [Related]
20. Effects of ring fluorination on the cardiovascular actions of dopamine and norepinephrine in the dog.
Goldberg LI; Kohli JD; Cantacuzene D; Kirk KL; Creveling CR
J Pharmacol Exp Ther; 1980 Jun; 213(3):509-13. PubMed ID: 6894165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
